By STAT Editorial Staff
The biotechnology sector finds itself in a paradoxical state. On one hand, the pace of scientific innovation has arguably never been faster; gene therapies, mRNA platforms, and artificial intelligence-driven drug discovery are turning once-incurable diseases into manageable conditions. Yet, beneath this veneer of unprecedented progress, the structural foundations that allow these breakthroughs to reach patients are beginning to crumble.
This is the central thesis of Jeremy Levin, a veteran industry titan, former CEO of Teva Pharmaceuticals, and the current chairman of Ovid Therapeutics. In his new book, Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust, Levin sounds an alarm that has been echoing through boardrooms and regulatory hallways: the institutions—regulators, financial markets, and public faith in science—that nurture the industry are under siege.
In a wide-ranging interview on this week’s episode of The Readout Loud, hosted by Adam Feuerstein, Allison DeAngelis, and Elaine Chen, Levin detailed the systemic risks facing biotech. He argues that the industry is at a precarious inflection point, where political volatility, short-termist investment cycles, and a pervasive, corrosive distrust in scientific authority could derail the next generation of medical miracles.
The Main Facts: A Sector Under Siege
The core argument of Levin’s critique is that biotechnology is not merely a commercial venture but a strategic pillar of national and global security. When that pillar is shaken by external political and economic forces, the consequences are not just financial—they are human.
Levin identifies three primary drivers of this instability:
- The Erosion of Regulatory Predictability: As the FDA and other global regulatory bodies face increasing political pressure, the clarity and stability of the approval process have become muddled.
- The Short-Termism of Wall Street: The influx of speculative capital, followed by sharp market contractions, has forced companies to prioritize quarterly earnings and "quick wins" over the decade-long, high-risk development cycles required for truly transformative medicine.
- The Crisis of Public Trust: The post-pandemic landscape has left the scientific establishment vulnerable to partisan attacks. This skepticism makes it harder to recruit for clinical trials, harder to pass necessary legislation, and harder to secure the social license to operate.
"When an institution such as this, which is critical, is shaken, the industry must stand firm," Levin noted during the podcast. "It must call out why this is a problem. The titans are dead silent right now."
Chronology: The Evolution of a Strategic Industry
To understand the current crisis, one must look at the historical trajectory of the biotech industry.
- The Golden Era (1980s–2000s): The industry was characterized by a symbiotic relationship between academic research, government grants (NIH), and a nascent but patient venture capital community. The regulatory framework was largely viewed as a partner in ensuring safety while fostering innovation.
- The Globalization Phase (2010s): As biotech grew into a multi-hundred-billion-dollar industry, it became a focal point for global trade policy. Companies expanded rapidly across borders, relying on a complex, interconnected global supply chain that worked efficiently—until it didn’t.
- The COVID-19 Catalyst (2020–2022): The pandemic brought unprecedented speed to drug development. However, it also politicized science. The rapid development of vaccines, while a triumph of biotechnology, was met with misinformation campaigns that undermined the very regulatory bodies that oversaw the breakthroughs.
- The Current Correction (2023–Present): Following the pandemic boom, the market has undergone a significant "reset." Investors have retreated from early-stage, high-risk assets, and the political climate has shifted toward increased scrutiny of drug pricing, culminating in legislation like the Inflation Reduction Act (IRA), which has fundamentally changed how companies approach R&D investment.
Supporting Data: Where the Balance Tips
Levin’s warnings are not based on anecdotal evidence alone; they are reflected in the shifting landscape of industry data.
- R&D Capital Allocation: According to recent market analysis, venture capital investment in early-stage biotech has become increasingly concentrated. While the total number of startups remains high, "follow-on" funding—the capital required to carry a drug through Phase 2 and Phase 3 trials—has become significantly harder to secure. This leads to a "valley of death" where promising science is abandoned for lack of runway.
- Clinical Trial Enrollment: Data from the past three years indicates that public participation in clinical trials has become more difficult in specific demographic groups, partly due to the politicization of health data and scientific research.
- Regulatory Timelines: While the FDA continues to approve a high number of innovative therapies, the predictability of those approvals is increasingly questioned by industry analysts. The time between initial meetings and final labeling negotiations has fluctuated, creating a climate of uncertainty that makes it difficult for companies to forecast their own viability.
Official Responses and Industry Sentiment
The silence from "the titans"—the leaders of the largest pharmaceutical companies—has been a major point of contention for Levin. During the Readout Loud interview, he addressed the tendency for major pharma executives to avoid public confrontation with policymakers.
"There is a fear that by speaking out against regulatory overreach or political interference, these companies will face retaliation," Levin explained. "But silence is its own form of complicity. If you represent the backbone of the global health infrastructure, you have a fiduciary and ethical duty to ensure the systems you operate within remain stable."
Industry trade groups, such as BIO (the Biotechnology Innovation Organization), have occasionally pushed back on specific policy changes, but Levin argues that these efforts are often fragmented and reactive. He calls for a more unified, proactive stance that emphasizes the strategic necessity of a healthy biotech sector, rather than just the profit margins of individual firms.
Implications: The High Cost of Inaction
If the current trajectory continues, the implications for patients are severe.
1. The "Innovation Drain"
If the regulatory and investment environments become too hostile, the brightest scientific minds will move elsewhere. We are already seeing an increase in biotech startups looking toward Europe or Asia for clinical trial support and initial capital, simply because the domestic climate in the U.S. has become too unpredictable.
2. A Narrowing Focus
When capital is scarce and the path to approval is uncertain, companies inevitably retreat to "safe" bets. This means less investment in high-risk, high-reward areas like Alzheimer’s, rare genetic disorders, or complex neurodegenerative diseases. We risk entering an era of "me-too" drugs—incremental improvements on existing products—rather than the radical breakthroughs that defined the last forty years.
3. The Erosion of the Social Contract
Biotech relies on the public’s willingness to participate in trials and their belief that the medicines produced are safe and effective. If that trust is lost, the cost of drug development will skyrocket, as the industry spends more on "rebuilding the brand" of science than on actual research.
A Call to Action
Levin’s book and his commentary on The Readout Loud serve as a manifesto for reform. He advocates for:
- Legislative Stability: Providing long-term tax incentives that are decoupled from the partisan election cycle.
- Regulatory Dialogue: Moving toward a more transparent, predictable FDA review process that treats companies as partners in public health rather than adversaries.
- Public Engagement: A concerted effort by the industry to communicate the value of its work to the general public, moving away from opaque corporate speak and toward a narrative of human benefit.
As the biotech industry looks toward the next decade, the challenge is clear: it must decide whether it will remain a passive participant in its own decline or whether it will find the collective voice to advocate for the stability it needs to survive. The science is ready, but as Jeremy Levin argues, the institutions—and the leadership—must catch up before the balance shifts too far.
